Long-term stability of clinical-grade lentiviral vectors for cell therapy.

"Declaration of interests C.H.J is an inventor on patents and/or patent applications licensed to Novartis Institutes of Biomedical Research and receives license revenue from such licenses. C.H.J. is a scientific cofounder of Capstan Therapeutics, Bluewhale Bio, and Tceleron; is a consultant to Kite Pharma; and is a member of the Scientific Advisory Boards of AC Immune, Alaunos, BluesphereBio, Cabaletta, Carisma, Cartography Biosciences, Cellares, Celldex, Decheng, Poseida, Replay Bio, Verismo, and WIRB-Copernicus Group. A.C. is a scientific cofounder of Tceleron, and is a consultant to Kite Pharma and Bluewhale Bio. J.A.F. has received grants and personal fees from Cartography Biosciences, grants from Tmunity Therapeutics, and personal fees from Retro Bio and Shennon Bio outside the submitted work. In addition, J.A.F. holds patents related to CAR T cells for cancer that are licensed and associated with royalties."

"We acknowledge the UPenn Center for Advanced Retinal & Ocular Therapeutics and the Children’s Hospital of Philadelphia Clinical Vector Core as manufacturers of the LV lots. In addition, support for vector release testing at the time of production was provided by the National Gene Vector Biorepository at 10.13039/100006733Indiana University, which is funded through the 10.13039/100000050National Heart, Lung, and Blood Institute contract 75N92019D00018. We thank Drs. Saar Gill, Avery Posey, and Neil Sheppard for providing cell lines; Sophia Ngo and Amy Marshall for data confirmation; and Tmunity Therapeutics for allowing the inclusion of their data."